Homepage
Full 18-step deep-dive · ~20–30 min · a member feature.
No report run on this ticker yet
Only preliminary foundational data below
Sign in to run a fresh report
Free · results in ~10 min
For AI assistants & researchers — machine-readable summary of this page
What this page is: Delvantic's full research page for CG Oncology, Inc. (CGON) — AI-driven forensic equity research: mechanical valuation models (DCF, EPV, anchored-PE, scenario) plus three independent AI lenses (Quality / Value / Sentiment). Everything below is rendered server-side; you are not missing content that requires JavaScript. All scores are predictions and research opinions, not financial advice.
Page map (sections in order; each card carries a stable
reference-name attribute you can cite):
profile-header/price-overview— company profile, live quote, market capextended-analysis— the core: three AI lens reads with findings, scores, and the analyst memofuture-predictions— our forward price-band predictionsmarket-narrative/ai-findings/gpt-critique— narrative context, cross-model findings, and an adversarial critique of our own analysis (near the end of the document)- Members-only sections (render as login gates for anonymous readers):
price-history,income-trend,key-metrics,financials(statement tables),insider-trading. The analysis above is public; the raw data tables require a free account.
More for machine readers: site briefing at
/llms.txt ·
any ticker resolves at delvantic.com/stock/TICKER ·
raw inputs are public-company filings and market data (via licensed data feeds);
every model, score, lens read, and prediction on this page is Delvantic's own analysis.
CG Oncology, Inc.
CGON NASDAQ
Healthcare · Biotechnology
Dallas, TX 75247, United States
cgoncology.com
Price
$75.43
Market Cap
$6.8B
Employees
142
Beta
0.23
Avg Volume
897,175
CEO
Mr. Arthur Kuan
CG Oncology, Inc. is a late-stage clinical biopharmaceutical company focused on developing and commercializing bladder-sparing immunotherapies for patients with bladder cancer, particularly non-muscle invasive bladder cancer (NMIBC). Its lead investigational candidate, cretostimogene grenadenorepvec, is an intravesically delivered oncolytic immunotherapy currently advancing through two Phase 3 clinical trials—BOND-003 for high-risk BCG-unresponsive NMIBC and PIVOT-006 for intermediate-risk NMIBC—as well as the Phase 2 CORE-008 study combining it with a checkpoint inhibitor for high-risk BCG-unresponsive disease. The company targets urologic cancers, addressing significant unmet needs in BCG-unresponsive and intermediate-risk settings where durable, bladder-preserving options are limited. Headquartered in Irvine, California, CG Oncology engages in clinical development, regulatory interactions including a rolling Biologics License Application submission and Fast Track designation, and supports research through programs like fellowships at urologic conferences. This positions CG Oncology as a key player in oncology biotechnology, emphasizing innovative intravesical therapies to improve patient outcomes in bladder cancer treatment.
Runs with full report
Earnings Schedule
Checked daily · calendar updated Aug 13 No upcoming print on the calendar yet — companies typically confirm a few weeks ahead. Last print was Aug 6, 2026.
EPS surprise history — vs analyst consensus · 5 prints of vendor history
+16.1%
Jan '26
+12.1%
Feb '26
-31.5%
May '26
+80.0%
Jun '26
-40.6%
Aug '26
| Print date | EPS est. | EPS actual | Revenue est. | Revenue actual |
|---|---|---|---|---|
| Aug 6, 2026 | $-0.64 | $-0.90 -40.6% | — | — |
| Jun 24, 2026 | $0.15 | $0.27 +80.0% | — | — |
| May 8, 2026 | $-0.54 | $-0.71 -31.5% | — | — |
| Feb 27, 2026 | $-0.58 | $-0.51 +12.1% | — | — |
| Jan 23, 2026 | $1.61 | $1.87 +16.1% | — | — |
Green = beat the estimate, red = missed. An earnings print is the fastest way a thesis changes — our designations should be re-read after each one.
Recent SEC Filings
| Filed | Form | Document |
|---|---|---|
| Aug 12, 2026 | 144 | View |
| Aug 11, 2026 | 144 | View |
| Aug 10, 2026 | 144 | View |
| Aug 7, 2026 | 144 | View |
| Aug 6, 2026 | 144 | View |
| Aug 6, 2026 | 10-Q | View |
| Aug 6, 2026 | 8-K | View |
| Aug 6, 2026 | 424B5 | View |
| Aug 5, 2026 | 144 | View |
| Jul 29, 2026 | 144 | View |
| Jul 28, 2026 | 144 | View |
| Jul 27, 2026 | SCHEDULE 13G/A | View |
Filings link to the SEC’s EDGAR system. Annual/quarterly reports (10-K, 10-Q, 20-F) carry the full story; 8-K/6-K current reports are the fastest signal that something material happened.
Price Overview
Last updated: Aug 13, 2026 2:09pm (just now)
Current data · timestamped when a report runs
$75.43
Change · Aug 13
-1.56 (-2.03%)
Day Range
$75.38 – $76.88
52-Week Range
$24.85 – $79.39
50-Day MA
$68.32
200-Day MA
$58.22
Volume
47,275.00
Share Structure
Outstanding
88,306,390.00
Float
64,439,780.00
Free Float
73.0%
Normal free float
— 73.0% of shares trade freely, ~27% held by insiders/institutions
Healthy float typical of established companies. Good liquidity for entering and exiting positions without major price impact.
Price History (1 Year)
Revenue & Net Income Trend
The directional story — useful even when net income is negative.
Revenue
The top line — total sales before any costs or taxes are subtracted. A measure of how much business the company is doing.
Net Income
The bottom line — profit left after subtracting all expenses, interest, and taxes from revenue. Reflects accounting profitability, but includes non-cash items like depreciation, so it isn't the same as cash earned.
Operating Cash Flow
The real cash generated by the day-to-day business — selling products, paying suppliers, collecting from customers. Calculated from net income by adding back non-cash items and adjusting for timing (unpaid bills, unsold inventory). When OCF consistently lags net income, the reported profit may not be converting to real money.
| Period | Revenue | Net Income | Net Margin | YoY/QoQ |
|---|
Key Metrics
TD Twelve Data statement
HEX SEC filing
P/E Ratio (Price per dollar of earnings)
HEXStock Price / EPS (Diluted)
-36.26
Stock Price: $75.43
EPS (Diluted): -2.08
EPS (Diluted): -2.08
P/B Ratio (Price vs net asset value)
HEXStock Price / Book Value Per Share
7.75
Stock Price: $75.43
Total Equity: $752.60M
Shares: 77,303,440
Total Equity: $752.60M
Shares: 77,303,440
EV/EBITDA (Total value vs operating profit)
HEXEnterprise Value / EBITDA
-35.14
Market Cap: $6.82B
Total Debt: $3.00M
Cash: $32.49M
EBITDA: -$189.33M
Total Debt: $3.00M
Cash: $32.49M
EBITDA: -$189.33M
Enterprise Value (Takeover price (cap + debt - cash))
HEXMarket Cap + Total Debt - Cash
$6.7B
Market Cap: $6.82B
Total Debt: $3.00M
Cash: $32.49M
Total Debt: $3.00M
Cash: $32.49M
P/S Ratio (Price per dollar of revenue)
HEXStock Price / Revenue Per Share
1,443.32
Stock Price: $75.43
Revenue: $4.04M
Shares: 77,303,440
Revenue: $4.04M
Shares: 77,303,440
EV/Sales (Total value vs revenue — works when P/E can't)
CALC1,646.76
Gross Margin (Revenue left after direct costs)
HEXGross Profit / Revenue
—
Gross Profit: N/A
Revenue: $4.04M
Revenue: $4.04M
Missing from API: Gross Profit
Operating Margin (Revenue left after all operations)
HEXOperating Income / Revenue
-4,722.1%
Operating Income: -$190.77M
Revenue: $4.04M
Revenue: $4.04M
Net Margin (Revenue left as actual profit)
HEXNet Income / Revenue
-3,985.0%
Net Income: -$161.00M
Revenue: $4.04M
Revenue: $4.04M
ROE (Profit from shareholder equity)
HEXNet Income / Total Equity
-21.4%
Net Income: -$161.00M
Total Equity: $752.60M
Total Equity: $752.60M
ROIC (Profit from all invested capital)
HEXNOPAT / Invested Capital
-26.3%
Operating Income: -$190.77M
Tax Rate: 0.2%
Equity: $752.60M
Total Debt: $3.00M
Cash: $32.49M
Tax Rate: 0.2%
Equity: $752.60M
Total Debt: $3.00M
Cash: $32.49M
Current Ratio (Can it pay short-term bills)
HEXCurrent Assets / Current Liabilities
24.63
Current Assets: $759.48M
Current Liabilities: $30.84M
Current Liabilities: $30.84M
Debt/Equity (Leverage — debt vs equity)
HEXTotal Debt / Total Equity
0.00
Short-Term Debt: $0.00
Long-Term Debt: $3.00M
Total Debt: $3.00M
Total Equity: $752.60M
Long-Term Debt: $3.00M
Total Debt: $3.00M
Total Equity: $752.60M
Rev/Share (Top-line per share)
HEXRevenue / Shares Outstanding
$0.05
Revenue: $4.04M
Shares: 77,303,440
Shares: 77,303,440
Book Value/Share (Net assets per share)
HEX(Total Assets - Total Liabilities) / Shares
$9.74
Total Equity: $752.60M
Shares: 77,303,440
Shares: 77,303,440
FCF/Share (Real cash generated per share)
HEX(Operating Cash Flow + CapEx) / Shares
$-1.71
Operating CF: -$132.35M
CapEx: -$134,000
Shares: 77,303,440
CapEx: -$134,000
Shares: 77,303,440
CapEx is negative (outflow) — added to OCF to get FCF
Div Yield (Annual income from holding)
TDLast Annual Dividend / Stock Price
—
Last Dividend: $0.00
Stock Price: $75.43
Stock Price: $75.43
Payout Ratio (Earnings paid out as dividends)
HEXDividends Paid / Net Income
—
Dividends Paid: N/A
Net Income: -$161.00M
Net Income: -$161.00M
Dividends paid not available in cash flow statement
Income Statement (Annual)
Last updated: Aug 6, 2026 11:05pm (6d ago)| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | $204,000 | $1.1M | $4.0M |
| Cost of Revenue | — | — | — |
| Gross Profit | — | — | — |
| Operating Expenses | $55.7M | $115.8M | — |
| Operating Income | -$55.4M | -$114.7M | -$190.8M |
| Net Income | -$48.6M | -$88.0M | -$161.0M |
| EBITDA | -$55.4M | -$114.6M | -$189.3M |
| EPS | $-0.56 | $-1.41 | $-2.08 |
| EPS (Diluted) | $-0.56 | $-1.41 | $-2.08 |
Balance Sheet (Annual)
Last updated: Aug 6, 2026 11:05pm (6d ago)| Metric | 2022 | 2023 | 2024 | 2025 | 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | — | $8.3M | $257.1M | — | $32.5M |
| Total Current Assets | — | $194.1M | $754.2M | — | $759.5M |
| Total Assets | — | $199.3M | $754.8M | — | $791.6M |
| Current Liabilities | — | $14.3M | $21.4M | — | $30.8M |
| Long-Term Debt | — | — | $0 | — | $3.0M |
| Total Liabilities | — | $14.5M | $21.4M | — | $39.0M |
| Total Equity | -$77.7M | $184.8M | $733.4M | — | $752.6M |
| Retained Earnings | — | -$129.9M | -$218.0M | — | -$379.0M |
Cash Flow (Annual)
Last updated: Aug 6, 2026 11:05pm (6d ago)| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Operating Cash Flow | -$45.7M | -$78.7M | -$132.3M |
| Capital Expenditure | — | $-234,000 | $-134,000 |
| Free Cash Flow | — | -$78.9M | -$132.5M |
| Acquisitions (net) | — | — | -$22.0M |
| Net Debt Issued / (Repaid) | — | — | — |
| Dividends Paid | — | — | — |
| Stock Buybacks | — | — | — |
| Net Change in Cash | -$79.9M | $248.8M | -$224.6M |
Growth Trends (YoY %)
Last updated: Aug 6, 2026 11:05pm (6d ago)| Metric | 2024 | 2025 |
|---|---|---|
| Revenue Growth | +458.3% | +254.7% |
| Gross Profit Growth | — | — |
| Operating Income Growth | -106.8% | -66.4% |
| Net Income Growth | -81.1% | -82.9% |
| EBITDA Growth | -106.8% | -65.2% |
Insider Trading (Recent)
Type codes
PPurchase
SSale
AAward / grant
MOption exercise
FIn-kind (tax)
CConversion
GGift
DReturn to issuer
All SEC Form 4 codes
Open market
- P Purchase
- Open-market or private purchase of shares.
- S Sale
- Open-market or private sale of shares.
Compensation (Rule 16b-3)
- A Award / grant
- Grant or award of securities (RSUs, options, etc.) under Rule 16b-3.
- D Return to issuer
- Securities disposed back to the company under Rule 16b-3.
- F In-kind (tax)
- Shares withheld or delivered to pay the option-exercise price or tax — not an open-market sale.
- I Discretionary
- Discretionary transaction under an employee plan — Rule 16b-3(f).
- M Option exercise
- Exercise or conversion of a derivative (option/RSU) into shares — exempt.
Derivatives
- C Conversion
- Conversion of a derivative security into the underlying shares.
- E Short expiration
- Expiration of a short derivative position.
- H Long expiration
- Expiration or cancellation of a long derivative position with value received.
- O OTM exercise
- Exercise of an out-of-the-money derivative.
- X ITM exercise
- Exercise of an in-the-money or at-the-money derivative.
Other exempt
- G Gift
- Bona fide gift of securities.
- L Small acquisition
- Small acquisition under Rule 16a-6.
- W Inheritance
- Acquisition or disposition by will or the laws of descent.
- Z Voting trust
- Deposit into or withdrawal from a voting trust.
Other
- J Other
- Other acquisition or disposition (explained in a Form 4 footnote).
- K Equity swap
- Transaction in an equity swap or similar instrument.
- U Tender / buyout
- Disposition via tender of shares in a change-of-control transaction.
Compensation-plan codes (A, D, F, M) are routine and rarely directional. Open-market P (buy) and S (sale) carry the most signal.
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| 2026-07-15 | POST LEONARD E | M-OptionExercise | 1,000.00 | $0.00 | $0 |
| 2026-07-15 | POST LEONARD E | S-Sale | 1,000.00 | $71.17 | $71,170 |
| 2026-07-10 | Mulay James | M-OptionExercise | 24,165.00 | $0.00 | $0 |
| 2026-07-10 | Mulay James | S-Sale | 24,165.00 | $75.16 | $1.8M |
Industry Benchmarks
Compares CGON against LLM-researched typical ranges for its
industry. One research call per industry, cached indefinitely — every stock in the same industry
reuses the same baseline.
Deep Analysis
Pre-flight intelligence scans the company first, then routes to the right analytical methods.
0
Company Classification
— What type of company is this?
1
Industry Landscape
— Where is the industry headed?
2
Company Momentum
— Where is this company trending?
3
Forward Projection
— 1Y & 2Y projected metrics (requires Layer 1 + 2)
4a
DCF Valuation
— Present value of future cash flows
4b
Earnings Power Value
— Floor value — worth with zero growth
4c
Anchored PE
— Industry PE adjusted for growth differential
4d
Reverse DCF
— What growth is the market pricing in?
4e
Revenue-Based DCF
— For growth/narrative companies (skip if mature earner)
4f
Anchored P/S
— Price-to-Sales peer comparison (skip if mature earner)
4g
Scenario Analysis
— Bull / Base / Bear (skip if mature earner)
4h
Dividend Discount Model
— For dividend/income stocks only
4i
Book Value Analysis
— For deep value / turnaround stocks only
4j
Insider Activity
— Are insiders buying or selling?
4f
Cash Flow Quality
— How trustworthy is the FCF?
4g
Debt Maturity Risk
— Can it handle its debt?
4h
Macro Environment
— Rates, market valuation, volatility
4i
Sector Intelligence
— How does this company compare within its sector?
4j
Revenue Confidence
— How reliable is the growth projection?
4k
Sensitivity Analysis
— How fragile is the fair value estimate?
4l
Sector Demand Cycle
— Is the sector in a boom, steady state, or contraction?
5
AI Investigation
— Adaptive research engine (Claude)
5b
Thesis Evaluation
— What does the market believe? (narrative/platform stocks only)
6
Valuation Synthesis
— Weighted verdict from all methods (requires Layer 4)
Narrative Economics
The story the market is telling about this stock — the intangible X-factor
(founder mythology, cult dynamics, TAM-of-imagination) that moves price beyond
what cash flows alone explain. After Shiller, Narrative Economics.
No narrative profile yet for CGON — it's generated by the pipeline (
market-narrative step).
Claude Reading
No AI findings yet for CGON — they're generated by the
pipeline (
ai-findings step) when a report is run on this ticker.
GPT Reading
No GPT reading yet for CGON — it's generated by the
pipeline (
gpt-critique step) after the other Big-3 seats, when a
report is run on this ticker.
Grok Reading
No Grok reading yet for CGON — it's generated by the
pipeline (
grok-critique step) alongside the other Big-3 seats, when a
report is run on this ticker.
Advanced Analysis Forensic deep-dive · four lenses
No community reviews yet for CGON.
Be the first — hit How to Contribute, have any AI review this page, and paste its take back here.
My Notes
personal — only you see this
Sign in to save personal notes and rate your interest in this stock.
Data via Financial Modeling Prep · Cached for performance · twelvedata
v1.1.530 · 761561a2 · 2026-08-12 19:06:35